GET DAILY SIGNALSDirexion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) Delivers +22% Rebound Over 30 Days
Key Takeaways
- PILL is a 3x leveraged ETF that seeks 300% of the daily return of the S&P Pharmaceuticals Select Industry Index, magnifying both gains and losses.
- Over the last 30 days, PILL has climbed roughly 22%, rebounding from a mid-October low near $13.40 to about $16.77.
- The rally was driven by a broad pharmaceutical and biotech recovery during third-quarter earnings season and a post-election, risk-on shift in sentiment.
- The longer quarterly trend remains negative, with the fund still down roughly 17% from mid-August levels despite the recent bounce.
- Because PILL rebalances daily, its returns compound and can diverge significantly from three times the index over periods longer than a single day.
- Investors can explore detailed Price Targets, Earnings, and Forecast pages for additional analysis of this ticker.
Understanding PILL’s Structure and Role in the Market
PILL is the Direxion Daily Pharmaceutical & Medical Bull 3X Shares, a leveraged exchange-traded fund that seeks daily investment results, before fees and expenses, of 300% of the performance of the S&P Pharmaceuticals Select Industry Index. Launched in November 2017 and listed on NYSE Arca, the fund carries a net expense ratio of approximately 0.97% and is managed by Rafferty Asset Management. It relies on swaps, futures, and other derivatives to deliver its leveraged exposure.
The underlying index is a modified equal-weighted benchmark of pharmaceutical and medical stocks from the S&P Total Market Index, grouped under the GICS pharmaceuticals sub-industry. Because it is equal-weighted, mid- and small-cap names exert more influence than they would in a market-cap-weighted health care fund. In my view, most investors treat PILL as a short-term tactical vehicle for expressing a leveraged view on the sector, recognizing that it is non-diversified and intended for daily rather than extended holding periods. I also checked this using Tickeron’s AI Screener to see how the fund stacks up against other leveraged sector products.
Recent Price Action: +22% in 30 Days Versus the Quarterly View
Over the past 30 days PILL posted a solid rebound, advancing from a closing price of $13.70 on October 13 to roughly $16.77, for a gain of about 22%. The fund bottomed near $13.41 in mid-October before climbing through late October and early November, touching the upper $17 range at times.
Looking back over the quarter, the picture is less favorable. Three months ago PILL traded near $20 after peaking above $23 in mid-August. It then declined through September and early October before the recent recovery, leaving the fund down roughly 17% from those mid-August levels. This kind of volatility is typical for a 3x leveraged product that amplifies the daily moves of its underlying index in both directions.
Drivers Behind the 30-Day Advance
The +22% move was fueled by a broad recovery in pharmaceutical and biotech equities, magnified by PILL’s 3x daily leverage. Third-quarter earnings season supplied much of the fundamental support. Gilead Sciences (GILD) raised its full-year product sales outlook, Vertex Pharmaceuticals (VRTX) lifted its 2026 revenue guidance after completing an acquisition, and Amgen (AMGN) reported double-digit sales growth across much of its portfolio. Moderna (MRNA) raised its 2026 growth outlook and saw a price-target increase, while Eli Lilly (LLY) advanced on positive clinical data.
A post-election risk-on rally in early November added further momentum, with pharmaceutical and biotech names participating in the broader market advance. Because the index is equal-weighted, strength in mid- and small-cap names carried extra weight, and PILL’s leverage amplified those gains. The advance also reflected a rebound from oversold conditions built up during the September-to-October pullback.
Quarterly Context and the Impact of Daily Rebalancing
Over the past three months PILL’s path featured a steep decline followed by a partial recovery. After peaking above $23 in mid-August, the fund slid through September and early October amid a rotation out of health care and defensive sectors as interest-rate expectations shifted and market uncertainty rose. Several high-profile disappointments within the sector, including guidance cuts at certain biopharmaceutical companies, added to the weaker tone.
The rebound that started in late October was supported by better earnings results, guidance increases from major pharmaceutical firms, and renewed risk appetite. Because PILL targets 3x daily exposure and rebalances each day, the compounding effect of these swings can produce returns over weeks and months that differ substantially from a simple three-times multiple of the index’s cumulative move. This structural reality is central to understanding the fund’s sharp quarter-over-quarter volatility.
Key Factors to Monitor Going Forward
Several elements are likely to influence PILL’s direction ahead. Ongoing quarterly earnings reports and guidance updates from major pharmaceutical companies will remain important catalysts, along with upcoming FDA decisions and clinical trial readouts that can affect individual index constituents. Macroeconomic conditions, including inflation data and the trajectory of interest rates, will continue to drive sector rotation into and out of health care. Policy and regulatory developments, such as drug-pricing measures, also have the potential to shift sentiment across the pharmaceutical space.
For a leveraged fund like PILL, investors should also keep in mind the structural risks tied to daily 3x exposure, including volatility decay and the compounding of daily returns. These features make the fund unsuitable as a passive long-term holding, so tracking the underlying index’s daily movements remains essential rather than expecting straightforward three-times performance over longer intervals. From what I see, monitoring these daily dynamics closely helps put the fund’s moves in proper perspective.
Using Tickeron’s Trending AI Robots for Additional Perspective
I’ve found Tickeron’s Trending AI Robots page helpful when looking for systematic ways to complement manual analysis of leveraged products like PILL. The section curates a selection of the platform’s automated trading systems, highlighting top-performing bots across different strategies and timeframes. Each bot’s track record and methodology are shown so users can evaluate them against their own objectives, offering a data-driven starting point for those interested in automated approaches.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PILL's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for PILL moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 27 of the 28 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on PILL as a result. In 76 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for PILL just turned positive on October 20, 2026. Looking at past instances where PILL's MACD turned positive, the stock continued to rise in 45 of 48 cases over the following month. The odds of a continued upward trend are 90%.
PILL moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where PILL advanced for three days, in 288 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PILL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PILL broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PILL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Advertisement